Non-Hodgkin Lymphoma   

In a patient who relapsed following 2nd line transplant, how do you select CAR-T vs bispecifics vs non-T-cell-mediated therapies as outlined in NCCN? ...

Do you speak to different expectations re: ability to achieve PR/CR and/or how this will impact ability to get to later therapies for a patient with p...

Is the data sufficient to change your practice?

Does cumulative exposure to BTKi increase potential risk of cardiac toxicity?

Should pirtobrutinib be viewed as a bridge to CAR-T or transplant or a destination therapy?

How do you predict which patients may be in a high risk group and less likely to benefit from a second BTKi?

How would the risk of VTE associated with crizotinib affect your decision? Should we consider using crizotinib in combination with brentuximab?

Is an LP only recommended in the setting of particular subtypes of lymphoma or symptoms of CNS disease?

Do you prefer a cHL chemotherapy backbone or PMBL chemotherapy backbone?